Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Tolerability of Batoclimab in Adult Participants With CIDP
NCT07188844Phase 2Terminated
- Sponsor
- Immunovant, Inc.
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of batoclimab in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Immunovant, Inc.. Started Aug 2025; status: terminated.
02
Drugs
batoclimab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT07188844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07188844.